Drug profile · INN
betaine
CYSTADANE
betaine (CYSTADANE) is a betaine-homocysteine s-methyltransferase substrate. Associated with Recordati Rare Diseases Australia Pty.. Route of administration: oral. Current US regulatory status: approved.
Drug details — betaine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 1
- Data quality
- 0.89
Quick answer
betaine (CYSTADANE) is a betaine-homocysteine s-methyltransferase substrate. Associated with Recordati Rare Diseases Australia Pty.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Betaine-homocysteine S-methyltransferase substrate
Primary target: Betaine-homocysteine S-methyltransferase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is betaine?
betaine (CYSTADANE) is a betaine-homocysteine s-methyltransferase substrate. Associated with Recordati Rare Diseases Australia Pty.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for betaine?
CYSTADANE is a marketed brand name for betaine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of betaine?
betaine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.